The novel glycopolymer CD206 blockers presented in thiswork possess relatively uncommon SO4-3-Gal sugar functionalitieswhich, though reported to bind relatively weakly to P-selectin,66 appear to be specific for the CR domain of CD206,and thus may be utilized both to dissect CD206-binding glycan functionin vitro and to modulate its activity in vivo in the context of immunomodulationor prevention of pathogen infection. Here, MRC1 is linked to infection.